Macrogenics Inc. (MGNX)
Levi & Korsinsky Announces an Investigation on Behalf of MacroGenics, Inc. (MGNX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Is Investigating MacroGenics Inc And Calls On Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Commenced on Behalf of MacroGenics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MGNX Losses
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Is Probing MacroGenics Inc And Invites Its Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study. The press release summarized the research abstract's findings about Vobra Duo's safety profile, in which grade 3 events were under 32% for both doses and no deaths were reported.
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MGNX
NEW YORK, NY / ACCESSWIRE / July 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
The Schall Law Firm Is Conducting A Probe Into MacroGenics Inc And Urges Its Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating MacroGenics Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. Being Investigated on Behalf of MacroGenics, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics Inc Is Under Investigation By The Schall Law Firm And Its Shareholders Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MGNX
NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
An Investigation Has Commenced on Behalf of MacroGenics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MGNX Losses
NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
